Literature DB >> 2344673

Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension.

L Linder1, W Kiowski, F R Bühler, T F Lüscher.   

Abstract

In isolated blood vessels, acetylcholine releases endothelium-derived relaxing factor (EDRF). In vivo, the vasodilator action of acetylcholine may be mediated by EDRF, but prostacyclin or prejunctional inhibition of adrenergic neurotransmission may also be involved. Therefore, we investigated whether acetylcholine releases EDRF in humans in vivo and, if so, whether the response altered in essential hypertension. Acetylcholine was infused into the brachial artery, and forearm blood flow measured by venous occlusion plethysmography. In control subjects, acetylcholine (0.02-16 micrograms/min/100 ml tissue) increased flow from 2.4 +/- 5.0 to 20.6 +/- 5.2 ml/min/100 ml tissue (n = 14; p less than 0.05) and decreased forearm vascular resistance from 42.0 +/- 4.1 to 6.0 +/- 1.4 units (p less than 0.03), a response comparable to that of sodium nitroprusside (0.6 micrograms/min ml tissue). Acetylsalicylic acid (500 mg i.v.) given to block vascular prostacyclin production did not alter the response (n = 14). alpha-Adrenoceptor blockade by phentolamine (12 micrograms/min/100 ml tissue) did not prevent the increase in flow evoked by acetylcholine. In hypertensive patients, the decrease in forearm vascular resistance induced by acetylcholine but not evoked by sodium nitroprusside was reduced as compared with controls (14.5 +/- 3.1 and 6.1 +/- 1.6 units, respectively; n = 8; p less than 0.05). Thus, the vascular effects of acetylcholine in the human forearm circulation are independent of prostaglandins and adrenergic neurotransmission and therefore are most likely to be mediated by EDRF; the acetylcholine-induced release of EDRF is blunted in patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2344673     DOI: 10.1161/01.cir.81.6.1762

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  87 in total

Review 1.  Endothelial nitric oxide in humans in health and disease.

Authors:  P Vallance; A Hingorani
Journal:  Int J Exp Pathol       Date:  1999-12       Impact factor: 1.925

Review 2.  Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.

Authors:  Stefano Taddei; Agostino Virdis; Lorenzo Ghiadoni; Isabella Sudano; Antonio Salvetti
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications.

Authors:  I B Wilkinson; D J Webb
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

Review 4.  Serum uric acid as a cardiovascular risk factor for heart disease.

Authors:  M H Alderman
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

5.  Improvement of endothelial dysfunction as a surrogate endpoint in the treatment of hypertension.

Authors:  T Santoso
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

Review 6.  Endothelial regulation of vascular tone.

Authors:  P Vallance
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

7.  Physiological importance of nitric oxide.

Authors:  J Collier; P Vallance
Journal:  BMJ       Date:  1991-06-01

Review 8.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 9.  Drug Treatment of Hypertension: Focus on Vascular Health.

Authors:  Alan C Cameron; Ninian N Lang; Rhian M Touyz
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

10.  Protein restriction during pregnancy induces hypertension and impairs endothelium-dependent vascular function in adult female offspring.

Authors:  Kunju Sathishkumar; Rebekah Elkins; Uma Yallampalli; Chandra Yallampalli
Journal:  J Vasc Res       Date:  2008-10-29       Impact factor: 1.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.